JAB-30355 / Jacobio Pharma - LARVOL DELTA

Jacobio Pharma Announces 2024 Annual Results (PRNewswire) - "JAB-30355: The dose escalation is expected to be completed in the second half of 2025."

Trial status • Solid Tumor

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation (clinicaltrials.gov) - P1/2 | N=144 | Recruiting | Sponsor: Jacobio Pharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Oncology • Solid Tumor

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation (clinicaltrials.gov) - P1/2 | N=144 | Not yet recruiting | Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Metastases • New P1/2 trial • Oncology • Solid Tumor

JAB-30355: A highly potent, orally bioavailable p53-Y220C reactivator (AACR 2024) - "JAB-30355 is a highly potent, selective, and orally bioavailable p53-Y220C reactivator that will be tested in clinical space soon."

Gastric Cancer • Gastrointestinal Cancer • Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor • CDKN1A

Jacobio Pharma to Present Data of PARP7 Inhibitor and P53 Reactivator at the 2024 AACR Annual Meeting (PRNewswire) - "JAB-30355 exhibited dose-dependent anti-tumor activity, inducing tumor stasis or regression in multiple CDX and PDX models of ovarian cancer, pancreatic cancer, gastric cancer, and small cell lung cancer, with overall good tolerability."

Preclinical • Gastric Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Small Cell Lung Cancer • Solid Tumor

Jacobio Pharma Announces 2023 Annual Results (PRNewswire) - "P53 Y220C activator JAB-30355: The IND has been approved by U.S. FDA (Food and Drug Administration), and phase I clinical trial is expected to be initiated in the second half of 2024. Preclinical data will be presented at the AACR Annual Meeting 2024; BET inhibitor JAB-8263: A Phase II trial of JAB-8263 monotherapy or combination therapies is planned to be initiated in the second half of 2024. Clinical data will be published at the 2024 European Hematology Association (EHA) Congress; Aurora A inhibitor JAB-2485: RP2D is anticipated to be determined in Q2 2024."

New P1 trial • New P2 trial • P2 data • Preclinical • Trial status • Oncology